Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTA 901 (Cemdomespib) in Diabetic Peripheral Neuropathic Pain
NCT05895552Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cemdomespib in diabetic polyneuropathy (DPN), sponsored by Biogen. Started Jul 2023; status: terminated.
02
Drugs
cemdomespib
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05895552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895552.